Solid Biosciences SLDB
NASDAQ SLDB
$6.39 -0.01 (-0.08%)
As of: Oct 21, 2026 · 3:59 PM EDT

Solid Biosciences (SLDB) Operating Margin (2022)

Updated

Solid Biosciences (SLDB) reported Operating Margin of -1315.20% for FY2022, down 784.70 percentage points from -530.50% in FY2021.

Analysis

Solid Biosciences (SLDB) Operating Margin (2022) Analysis & Trends

  • According to Business Quant data, Operating Margin came in at -530.50% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Solid Biosciences 921.04 Mn -261.31 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -411.44%
API Access

Solid Biosciences Operating Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-margin&ticker=SLDB&period=max&api_key=YOUR_API_KEY